机译:SCC244(Glumetinib)的临床前评估,在依赖癌症模型中C-Met的新颖,有效和高选择性抑制剂
Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Div Antitumor Pharmacol Shanghai;
Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Div Antitumor Pharmacol Shanghai;
Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Div Antitumor Pharmacol Shanghai;
Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Div Antitumor Pharmacol Shanghai;
Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Div Antitumor Pharmacol Shanghai;
Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Div Antitumor Pharmacol Shanghai;
Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Div Antitumor Pharmacol Shanghai;
Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Div Antitumor Pharmacol Shanghai;
Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Div Antitumor Pharmacol Shanghai;
Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Div Antitumor Pharmacol Shanghai;
Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Dept Med Chem Shanghai Peoples R;
Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Dept Med Chem Shanghai Peoples R;
Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Dept Med Chem Shanghai Peoples R;
Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Div Antitumor Pharmacol Shanghai;
Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Div Antitumor Pharmacol Shanghai;
机译:SCC244(Glumetinib)的临床前评估,在依赖癌症模型中C-Met的新颖,有效和高选择性抑制剂
机译:AMG 337的体外和体内活性,一种强效和选择性的MET激酶抑制剂,在MET依赖的癌症模型中
机译:发现(S)-1-(1-(咪唑并[1,2-a]吡啶-6-基)乙基)-6-(1-甲基-1H-吡唑-4-基)-1H- [1, 2,3]三唑并[4,5-b]吡嗪(Volitinib)在临床开发中作为高度有效和选择性的间充质-上皮转化因子(c-Met)抑制剂
机译:蛋白表位模拟方法:一种创新的选择性和高效丝氨酸蛋白酶抑制剂的方法
机译:elF4E抑制剂Briciclib(在013105上)在各种临床前癌症模型中均显示出强大的抗癌活性。
机译:更正:有效和选择性的细胞周期蛋白依赖性激酶4和6抑制剂ribociclib(LEE011)是临床前癌症模型中的多功能组合伙伴
机译:SCC244(Glumetinib)的临床前评估(Glumetinib),一种新的,有效和高选择性和高选择性抑制剂在核依赖性癌症模型中